<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904176</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-058</org_study_id>
    <nct_id>NCT00904176</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects</brief_title>
  <official_title>Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine that Dapagliflozin has no effect on the&#xD;
      pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin when dapagliflozin is&#xD;
      coadministered with warfarin. Also, that Dapagliflozin has no effect on the PK of digoxin&#xD;
      when dapagliflozin is coadministered with digoxin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs</measure>
    <time_frame>216 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of dapagliflozin on the PK of R-warfarin, when warfarin and dapagliflozin are coadministered in healthy subjects (Cohort 1)</measure>
    <time_frame>16 time points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects</measure>
    <time_frame>16 time points</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin + Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin + Digoxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablets, Oral, 20 mg, followed by 10 mg, Single Dose</description>
    <arm_group_label>Dapagliflozin + Digoxin</arm_group_label>
    <arm_group_label>Dapagliflozin + Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Tablets, Oral, 25 mg, Single Dose</description>
    <arm_group_label>Dapagliflozin + Warfarin</arm_group_label>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Tablets, Oral, 0.25, Single Dose</description>
    <arm_group_label>Dapagliflozin + Digoxin</arm_group_label>
    <arm_group_label>Digoxin</arm_group_label>
    <other_name>Lanoxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination, ECGs, and clinical laboratory determinations&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²&#xD;
&#xD;
          -  Women who are not of childbearing potential (ie, who are postmenopausal or surgically&#xD;
             sterile) and men, ages 18 to 45&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WOCBP include any female who has experienced menarche and who has not undergone&#xD;
             successful surgical sterilization (hysterectomy, bilateral tubal ligation, or&#xD;
             bilateral oophorectomy) or is not postmenopausal&#xD;
&#xD;
          -  Any significant acute or chronic medical illness or relevant trauma (e.g. history of&#xD;
             chronic hypertension, bacterial endocarditis, hemorrhagic stroke, motor vehicle&#xD;
             accident resulting in significant head trauma or internal injuries)&#xD;
&#xD;
          -  History of important arrhythmias as determined by the Investigator, including but not&#xD;
             limited to ventricular fibrillation, ventricular tachycardia, A-V block,&#xD;
             Wolff-Parkinson-White Syndrome, and sinus bradycardia (defined in this study as heart&#xD;
             rate &lt; 50 bpm based on vital signs and ECG performed within 21 days of Study Day 1)&#xD;
&#xD;
          -  History or evidence of abnormal bleeding or coagulation disorder (e.g., history of&#xD;
             prolonged bleeding during dental procedures, pregnancy delivery, previous surgery or&#xD;
             injury) and/or having a first degree relative under 50 years of age with a history of&#xD;
             abnormal bleeding or coagulation disorder per patient's report&#xD;
&#xD;
          -  History of unexplained syncope&#xD;
&#xD;
          -  Presence of external hemorrhoids with signs of rectal bleeding on physical exam&#xD;
&#xD;
          -  Positive fecal occult blood (FOB), using the Hemoccult Sensa® assay (or equivalent),&#xD;
             or hematuria (more than trace), unless deemed not clinically significant by the&#xD;
             Investigator and Medical Monitor at screening or dosing&#xD;
&#xD;
          -  Platelet count &lt; 150,000 cells/µL at screening or dosing&#xD;
&#xD;
          -  INR or aPTT values above the upper limit of normal (ULN) at screening or dosing&#xD;
&#xD;
          -  Hemoglobin or hematocrit &lt; LLN at screening or dosing&#xD;
&#xD;
          -  Abnormal urinalysis at screening or dosing (repeat urinalysis may be allowed for&#xD;
             positive hematuria in women)&#xD;
&#xD;
          -  Glucosuria at screening or dosing&#xD;
&#xD;
          -  Abnormal liver functions tests (ALT, AST or total bilirubin &gt; 10% above ULN) at&#xD;
             screening or dosing&#xD;
&#xD;
          -  History of diabetes mellitus&#xD;
&#xD;
          -  History of heart failure&#xD;
&#xD;
          -  History of renal insufficiency&#xD;
&#xD;
          -  History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal&#xD;
             mycotic infections&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse either at screening or before dosing&#xD;
&#xD;
          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1,&#xD;
             -2 antibody&#xD;
&#xD;
          -  Protein C or Protein S deficiency&#xD;
&#xD;
          -  History of allergy to SGLT2 inhibitors or related compounds&#xD;
&#xD;
          -  History of allergy to warfarin or related compounds&#xD;
&#xD;
          -  History of allergy to digoxin or related compounds&#xD;
&#xD;
          -  Prior exposure to dapagliflozin within 3 months of Day -1&#xD;
&#xD;
          -  Exposure to any investigational drug or placebo within 4 weeks of Day -1&#xD;
&#xD;
          -  Use of any prescription drugs within or over-the-counter acid controllers or vitamin K&#xD;
             containing products within 4 weeks prior to study drug administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pra International</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3648&amp;filename=MB102-058_redacted%20_CSR%20_synopsis.pdf</url>
    <description>MB102-058_redacted _CSR _synopsis</description>
  </link>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2009</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

